Related Experiment Video
Updated: Aug 23, 2026

DNA Vector-based RNA Interference to Study Gene Function in Cancer
Published on: June 4, 2012
[Experimental research of targeting hTERT gene inhibited in hepatocellular carcinoma therapy by RNA interference]
Peng-Hui Zhang1, Zhi-Guang Tu, Ming-Qing Yang
1Faculty of Laboratory Medicine, Chongqing University of Medical Sciences, Chongqing,400016, PR China.
Background & Objective:
RNA interference (RNAi) is a new gene blocking technology that silences target gene at post-transcription level induced by the small interference RNA (siRNA). RNAi has been demonstrated great prospect in gene functional research and gene therapy areas. Nowadays, RNAi has been reported to be used to inhibit the expression of endogenous genes including cyclophilin, GAPDH, p53, and c-myc; and there were some progresses in the therapy of the diseases caused by AIDS and hepatitis viruses with RNAi. However, hTERT gene, which was highly expressed in hepatocellular carcinoma and other malignant neoplasm, has not been researched by RNAi. In present research, we utilized RNAi to inhibit hTERT gene expression in vitro and in vivo, investigated the feasibility and specificity of gene therapy for hepatocellular carcinoma.
Methods:
Small interference RNAs homologous to hTERT gene were designed,pTZU6+1-shRNA-hTERT vector was constructed and transfected into hepatocellular carcinoma SMMC-7721 cells and transplanted SMMC-7721 tumor in nude mice to induce RNAi. The changes of hTERT gene expression and tumor cell proliferation in both siRNA treatment groups and control group were determined by flow cytometry, reverse transcription polymerase chain reaction (RT-PCR), immunochemistry in vitro and in vivo.
Results:
The expression of hTERT had been obviously inhibited by RNAi in vitro. The inhibition rate of cell growth was 37.5% after pTZU6+1-shRNA-hTERT vector was transfected to hepatocellular carcinoma SMMC-7721 cells; the phase of cell cycle indicated the reduction of S phase, while G(1)/G(0) phase increased. The mRNA level of hTERT decreased from 99.4% to 53.1%, its protein expression reduced from 86.3% to 46.6%. The tumor size reduced after treated with pTZU6+1-shRNA-hTERT vector in vivo; hTERT mRNA level decreased from 99.1% to 76.2%, and its protein expression decreased from 87.2% to 61.8% in siRNA treatment group. In contrast, there were no changes in control groups in vitro and in vivo.
Conclusion:
RNAi inhibits the hTERT gene expression and proliferation of hepatocellular carcinoma SMMC-7721 cells with specificity, and is a possible new approach for neoplasm gene therapy.
Insights
RNA interference effectively inhibits human telomerase reverse transcriptase (hTERT) gene expression in hepatocellular carcinoma cells and tumors. This targeted gene silencing offers a promising new avenue for neoplasm gene therapy.
Area of Science:
- Molecular Biology
- Gene Therapy
- Oncology
Context:
- RNA interference (RNAi) is a post-transcriptional gene silencing technology utilizing small interfering RNA (siRNA).
- hTERT gene is highly expressed in hepatocellular carcinoma (HCC) and other malignant neoplasms.
- Previous RNAi applications have shown promise in functional genomics and treating viral diseases, but not specifically for hTERT in HCC.
Purpose:
- To investigate the feasibility and specificity of RNA interference for inhibiting human telomerase reverse transcriptase (hTERT) gene expression in hepatocellular carcinoma.
- To evaluate the therapeutic potential of targeting hTERT in HCC through in vitro and in vivo studies.
Summary:
- Small interfering RNAs (siRNAs) targeting hTERT were designed and delivered via the pTZU6+1-shRNA-hTERT vector into HCC SMMC-7721 cells and xenograft tumors in nude mice.
- In vitro studies showed significant inhibition of hTERT mRNA and protein expression, leading to a 37.5% reduction in cell growth and altered cell cycle distribution (decreased S phase, increased G1/G0 phase).
- In vivo studies demonstrated reduced tumor size, with significant decreases in hTERT mRNA (from 99.1% to 76.2%) and protein expression (from 87.2% to 61.8%) in the siRNA treatment group compared to controls.
Impact:
- RNAi demonstrates specific inhibition of hTERT gene expression and proliferation in hepatocellular carcinoma cells.
- This study validates RNAi as a potential novel gene therapy approach for managing hepatocellular carcinoma and other neoplasms.
- Targeting hTERT via RNAi offers a new strategy for cancer treatment by disrupting a key oncogenic pathway.
Related Concept Videos
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

